CHOSA Oncology AB Logo

CHOSA Oncology AB

Develops diagnostics and targeted therapies to personalize platinum-based cancer treatments.

CHOSA | SPGR

Overview

Corporate Details

ISIN(s):
SE0007784319
LEI:
5493002SFL9YXB0A0027
Country:
Sweden
Address:
C/O Medicon Village, C/O Medicon Village, Scheeletorget 1, 223 81 Lund
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

CHOSA Oncology AB is a biotechnology company focused on advancing precision oncology. The company's core product is Platin-DRP®, a patented diagnostic test that analyzes a 205-gene signature from a patient's tumor to predict their response to platinum-based chemotherapies, including cisplatin and carboplatin. This technology enables personalized treatment strategies, aiming to improve survival rates and avoid unnecessary toxicity for non-responding patients. The company is also developing LiPlaCis®, a novel liposomal formulation of cisplatin designed for targeted drug delivery to tumors, thereby reducing systemic side effects. CHOSA's technologies are primarily aimed at cancers such as lung, breast, bladder, and endometrial.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CHOSA Oncology AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CHOSA Oncology AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CHOSA Oncology AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America N/A
MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan 9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan 9227
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan 3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan 4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea 417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden MODTX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland MOC
Mural Oncology PLC Logo
Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.
N/A

Talk to a Data Expert

Have a question? We'll get back to you promptly.